Angiogenic factors in blood serum of bone tumor patients

Klin Lab Diagn. 2013 Oct:(10):63-5, 31-3.
[Article in English, Russian]

Abstract

It is proven that angiogenesis and cartilage resorption processes involving vascular endothelial growth factor (VEGF) and its receptors play an important role in bone tissue regeneration and bone tumor development. A comparative analysis of VEGE VEGF-R1, VEGF-R2 and angiogenin content in blood serum of healthy persons, and patients with primary malignant, benign and borderline bone tumors was performed. 366 bone tumor patients aged 14-76 years were examined; 223 (60,9%) male and 143 (39,1%) -female. Control group included 48 practically healthy subjects aged 15-69 years; 25 (52,1%) male and 23 (47,9%) female. Serum VEGE VEGF-R1, VEGF-R2 and angiogenin concentrations measured using standard ELISA kits produced by "R&D Systems Inc. ", USA. It was shown that long-term treatment outcome (3-years overall survival) of typical osteosarcoma patients depended on tumor malignancy grade (determined by the criterion G). Baseline serum VEGF, its soluble receptors and angiogenin concentrations had no predictive value.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bone Neoplasms / blood*
  • Case-Control Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteosarcoma / blood*
  • Ribonuclease, Pancreatic / blood*
  • Vascular Endothelial Growth Factor A / blood*
  • Vascular Endothelial Growth Factor Receptor-1 / blood*
  • Vascular Endothelial Growth Factor Receptor-2 / blood*

Substances

  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2
  • angiogenin
  • Ribonuclease, Pancreatic